Novo Nordisk Awiqli, the first FDA-approved once-weekly basal insulin for type 2 diabetes, has launched nationwide across more than 70,000 US pharmacies, cutting basal injections from seven per week to one.
Eli Lilly’s once-weekly insulin, efsitora alfa, has shown promising results in Phase 3 clinical trials. The innovative treatment demonstrated A1C reductions comparable to daily basal insulins, with a consistent safety profile.
In addition to being the first to examine the safety and effectiveness of an automated insulin delivery (AID) system in conjunction with an Abbott FreeStyle Libre® 2 family sensor
Blood-glucose response hacking by synthetic biologists’ creates a chemotherapy detector
Pancreatic beta cells (β-cells) are the only cells that can produce insulin, and a significant cause of diabetes is a reduction in these cells
